We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
LONDON--AstraZeneca PLC (AZN.LN) said Friday it got approval for ZS-9, its drug against hyperkalaemia, from the committee for medicinal products for human use of the European medicines agency.
Hyperkalaemia is a condition characterized by high potassium levels in the blood serum caused by cardiovascular, renal and metabolic diseases.
Shares at 1245 GMT down 22 pence, or 0.5%, at 4578.5 pence valuing the company at GBP57.93 billion.
-Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
February 24, 2017 08:02 ET (13:02 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
